GILUPI GmbH and SCIENION AG announced on March 18that the companies intend to intensify their collaboration in the field of single circulating tumor cell (CTC) analysis. CTCs are rare cells that can be found in the peripheral blood of cancer…
Cardio-microcurrent device for chronic heart failure: first-in-human clinical study
Most devices for treating ambulatory Class II and III heart failure are linked to electrical pulses. However, a steady electric potential gradient is also…
Lab to market is a program for researchers in
Advanced Materials. If you are considering commercialising your technology, this program is for you.
We aim to turn scientists into science entrepreneurs.
Are you doing research in Advanced…
The Advanced Materials Competition (AdMaCom) is a fast-paced 2 week Accelerator Program for Startups in Advanced Materials.
AdMaCom focuses on: IP Strategy, Investment & funding opportunities, Technical & Business Mentoring, Pitch training and…
Rubbers & plastics for the automotive industry
SCIENION AG, located in the Technology Park Adlershof since its foundation in 2001, today announced that the expanding company will build larger new headquarters at Wagner-Régeny Street in the same district of Berlin.
• Proceeds will facilitate development of GeneQuine’s gene therapy pipeline for musculoskeletal disorders and vector platform
• Lead gene therapy candidate GQ-303, a potentially disease-modifying treatment for osteoarthritis, will be advanced to…
GlycoBody to be integrated into ONK pre-clinical program ONKT103, for solid tumors.
The drug delivery specialist Alrise Biosystems GmbH has entered into an Asset Purchase and Exclusive License Agreement with Ferring International Center S.A. for the development and commercialisation of products manufactured with Alrise’s ImSus®…
- Series E round led by existing top-tier life science investors Wellington Partners and HBM Healthcare Investments
- Data from AdrenOSS-2 on early treatment start with Adrecizumab in septic shock to be presented at DIVI, December 2-4, 2020
